Why IMV Wants You to Rethink What You Know About Immunotherapy — Q&A with CEO Frederic Ors – Equities.com
Equities.com |
Why IMV Wants You to Rethink What You Know About Immunotherapy — Q&A with CEO Frederic Ors
Equities.com Unlike traditional oncology methods, immunotherapies aim to trigger native responses of the body's own immune system to attack cancer cells. But there's a critical flaw in this approach, and it's one that could significantly limit the potential for … |
